ClinicalTrials.Veeva

Menu

Neonatal Seizure Registry - Developmental Functional EValuation (NSR-DEV)

University of California San Francisco (UCSF) logo

University of California San Francisco (UCSF)

Status

Completed

Conditions

Neonatal Seizure
Epilepsy
Stroke
Cerebral Palsy
Intracranial Hemorrhages
Intellectual Disability
Hypoxic-Ischemic Encephalopathy

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT04337697
1R01NS111166-01A1 (U.S. NIH Grant/Contract)
19-28584
R01NS111166 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The NSR-DEV study is a longitudinal cohort study of around 280 Neonatal Seizure Registry participants that aims to evaluate childhood outcomes after acute symptomatic neonatal seizures, as well as examine risk factors for developmental disabilities and whether these are modified by parent well-being.

Full description

Neonatal seizures due to brain injury (acute symptomatic seizures) are associated with high risk of neurodevelopmental disability in infancy. Although prognosis in early childhood is a critical question for parents and providers, outcomes beyond infancy are largely unknown. Further, parents of infants with neonatal seizures are at risk for mental health disorders, which can undermine their ability to care for a child with medical complexity and may contribute to impaired child development.

The NSR-DEV study is a longitudinal cohort study of around 280 Neonatal Seizure Registry participants enrolled at one of nine sites across the USA. Participants will be evaluated using developmental questionnaires and in-person neurodevelopmental testing. Parent well-being will be assessed at each time point.

Enrollment

188 patients

Sex

All

Ages

2 to 8 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Enrolled in NSR-II
  • Alive at the start of the NSR-DEV study period
  • Parent(s) who are English or Spanish literate (with assistance of interpreter)

Exclusion criteria

  • Neonates who were found to have exclusion criteria after NSR-II enrollment
  • Risk for adverse outcome independent of seizures and underlying brain injury (including but not limited to: inborn errors of metabolism, fetal infection, brain malformation)
  • Transient cause for seizures (e.g., mild hypoglycemia, hyponatremia, hypocalcemia with normal neuroimaging)
  • Neonatal-onset epilepsy syndromes

Trial contacts and locations

9

Loading...

Central trial contact

Hannah C. Glass, MDCM, MAS; Yasmeen A. Rezaishad, BS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems